AKBA

Akebia Therapeutics Stock Analysis

AI Rating

Great
  • Quality4/10
  • Growth↑ 8/10
  • Value↑ 8/10
Akebia Therapeutics sales and earnings growth
AKBA Growth
Good
  • Revenue Y/Y↑ 47.46%
  • EPS Y/Y↑ 93.94%
  • FCF Y/Y↑ 267.22%
Akebia Therapeutics gross and profit margin trends
AKBA Profitability
Great
  • Gross margin ↑ 83.30%
  • EPS margin↓ -2.30%
  • ROIC 5Y↑ -31.16%
Akebia Therapeutics net debt vs free cash flow
AKBA Risk
Great
  • Debt / Equity↓ 1.5
  • Debt / FCF↓ 0.0
  • Interest coverage↓ 0.9

Akebia Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗